Is Optimi Health Corp. (OPTH) a Buy, Sell, or Hold?
NASDAQ : OPTH
Optimi Health Corp.
$4.85 USD
-$0.16 (-3.19%)
- Volume
- 5.78K
- Average Volume
- 211.88K
- Market Capitalization
- $15.62M
- P/E Ratio
- -4.06
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $6.40
- Year Low
- $4.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.06
Company Overview
NASDAQ
Dane Stevens
Drug Manufacturers - Specialty & Generic
Healthcare
OPTH
6
CA
USD
Liquidity Metrics
1.86
0.06
0.03
0.01
0.00
Sales & Valuation
$426.9K
94.44
6.19
-6.65
-1.02
Profitability
-$1.1640000000000001
-$3.72M
-2330.08%
-2330.08%
-94.46%
-39.99%
P/E Metrics
-4.06
0.19
0.19
Analyst Price Target & Rating
1/5
0 Analysts
%
Poll Results
No votes yet today — be the first to share your view!
About Optimi Health Corp. (NASDAQ:OPTH) Stock
Based in Princeton, Canada, Optimi Health Corp., established in 2020, is a Canadian entity focused on manufacturing pharmaceutical and nutraceutical products. The company produces and supplies controlled substances, including finalized MDMA and psilocybin drug products, directly to authorized clinics, pharmacies, research trials, and collaborative partners. Their diverse product portfolio extends to MDMA, natural psilocybin, psilocin, other psychedelic compounds, and functional mushrooms, all derived from botanical sources and aimed at the health and wellness market. Optimi Health's operations span cultivation, processing, and distribution of raw mushroom biomass, alongside the creation of mushroom extracts, pharmaceutical drug products, and dietary supplements. These items are available f ... or purchase through the Amazon marketplace, via distributors and brokers, and directly online.
2026-06-29 11:13:00
/PRNewswire/ - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of
2026-06-29 09:00:00
Optimi's 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression. The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in September 2025.
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
2026-06-16 08:30:00
Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages. The products are available to qualified, authorized clinical research organizations.
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
2026-06-10 14:24:00
/PRNewswire/ - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
2026-06-10 09:15:00
The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from Health Canada and import authorization from the UK Home Office The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from Health Canada and import authorization from the UK Home Office
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
2026-06-08 13:00:00
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development PR Newswire VANCOUVER, BC,
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
2026-06-08 12:54:00
/PRNewswire/ - via IBN - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
2026-06-08 08:00:00
Recent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access Ibogaine is under investigation to treat PTSD, opioid use disorder and traumatic brain injury VANCOUVER, British Columbia, June 08, 2026 (GLOBE NEWSWIRE) -- via IBN – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today provided an update on its recently announced Ibogaine Initiative . Optimi has secured naturally derived ibogaine from two sources, in both hydrochloride (HCl) and freebase form.
Frequently Asked Questions
-
What is the current Optimi Health Corp. (OPTH) stock price?
-
Optimi Health Corp.(NASDAQ:OPTH) stock price is $4.85 in the last trading session. During the trading session, OPTH stock reached the peak price of $6.4 while $4 was the lowest point it dropped to. The percentage change in OPTH stock occurred in the recent session was --3.19% while the dollar amount for the price change in OPTH stock was -$0.16.
-
OPTH's industry and sector of operation?
-
The NASDAQ listed OPTH is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of OPTH?
-
Ann Little | Human Resources Manager
Leah Hodges | Corporate Secretary
John James Wilson | Co-Founder & Chairman
Jacob Safarik | Interim CFO & Director
Dane Stevens | Co-Founder, Chief Executive Officer, Chief Marketing Officer & Director -
How many employees does OPTH have?
-
Number of OPTH employees currently stands at 6. OPTH operates from 269 David Brown Way, Princeton, BC V0X 1W0, CA.
-
Link for OPTH official website?
-
Official Website of OPTH is: https://www.optimihealth.ca
-
How do I contact OPTH?
-
OPTH could be contacted at phone #778-761-4551 and can also be accessed through its website. OPTH operates from 269 David Brown Way, Princeton, BC V0X 1W0, CA.
-
How many shares of OPTH are traded daily?
-
The average number of OPTH shares traded daily for last 3 months was 211.88K.
-
What is the market cap of OPTH currently?
-
The market value of OPTH currently stands at $15.62M with its latest stock price at $4.85